Takeda Escapes COVID Impact With 2% Underlying Growth
R&D Spend To Rise 15%
Takeda continued to prove largely resistant to the business impact of the pandemic last fiscal year, when it made solid progress and exceeded a number of post-Shire targets. R&D spending is set to ramp-up as the Japanese firm progresses its 'Wave 1' pipeline to market.
You may also be interested in...
Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.
In a widely anticipated move, Takeda has confirmed the sale of its consumer healthcare business in Japan, to the US private equity group Blackstone.
In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.